Oncocyte Corporation — FY2021 Form 10-K
Entity note: The supplied filing is Oncocyte Corporation’s Form 10-K, not a filing under the name “Insight Molecular Diagnostics Inc.” It covers the fiscal year ended December 31, 2021, with 2020 comparisons, and was filed March 11, 2022. Oncocyte is a molecular diagnostics company developing and commercializing laboratory-developed tests (LDTs) and providing pharmaceutical services.
Business context
Oncocyte’s commercial focus was DetermaRx, a test intended to help identify early-stage lung cancer patients who may benefit from chemotherapy. DetermaIO, for immunotherapy response assessment, was available through research and biopharma services, including an Early Access Program launched in Q4 2021. The Chronix acquisition added blood-based cancer-monitoring and transplant-monitoring technologies, including DetermaCNI. The company also operates Pharma Services for pharmaceutical and biotechnology customers.
Financial results and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $7.727 million | $1.216 million |
| Gross profit (loss) | $0.188 million | $(0.639) million |
| Gross margin | Approximately 2.4% | Negative |
| Operating loss | $(74.212) million | $(29.711) million |
| Net loss | $(64.097) million | $(29.932) million |
| Net loss per share, basic and diluted | $(0.72) | $(0.46) |
| Net cash used in operating activities | $(35.941) million | $(25.980) million |
FY2021 revenue comprised DetermaRx ($2.475 million; 32%), Pharma Services ($1.460 million; 19%), and licensing ($3.792 million; 49%). Licensing revenue was new in 2021. Revenue grew 535%, but operating expenses and the reported loss also rose substantially. Operating expenses included a $27.266 million noncash increase in contingent-consideration fair value, primarily associated with Chronix. A $9.261 million income tax benefit largely reflected a partial release of valuation allowance related to acquired intangible assets; it did not reflect operating profitability.
At year-end, cash and cash equivalents were $35.605 million, marketable equity securities were $0.904 million, and restricted cash was $1.700 million. Current assets were $39.143 million versus current liabilities of $14.120 million. The company reported total liabilities of $94.346 million, including $1.313 million of current loans payable, $3.545 million of noncurrent lease liabilities, and $76.681 million of noncurrent contingent-consideration liabilities. Operating cash burn increased year over year. Financing activities provided $78.364 million, principally from equity issuance and exercises of options and warrants. Management stated that available cash and marketable securities were expected to fund current operations for at least twelve months from issuance of the financial statements; it also said additional capital would be needed unless revenue grows enough to cover operating expenses.
Material changes and unusual items
- Revenue rose to $7.727 million from $1.216 million, with most of the increase reflecting newly recognized licensing revenue and the expanded businesses.
- Oncocyte acquired the remaining Razor interests in February 2021 and acquired Chronix in April 2021. These transactions expanded its test pipeline and added operations, assets, and contingent payment obligations.
- Contingent-consideration liabilities increased to $76.681 million at year-end, including $69.621 million related to Chronix. The company recorded a $27.266 million FY2021 fair-value loss on contingent consideration; valuation depends on management estimates of future revenue, milestones, timing, and discount rates.
- Common shares outstanding increased from 69.1 million to 92.2 million during 2021. The company raised substantial equity capital, including through registered offerings and an at-the-market program.
- The $1.141 million Paycheck Protection Program loan and accrued interest were forgiven in May 2021, producing a gain on extinguishment of debt.
- In January 2022, Oncocyte entered into a collaboration with Life Technologies Corporation to develop and commercialize IVD versions of Oncomine Comprehensive Assay Plus and DetermaIO on Thermo Fisher’s Genexus platform. The agreement includes development-cost allocation, revenue sharing, milestones, and exclusivity terms; it is a subsequent event, not FY2021 revenue.
Outlook, risks, and audit
The filing provides no formal quantitative revenue or earnings guidance. Management expected continued research, development, sales, and marketing spending, and identified reimbursement progress and commercial adoption as important to future growth. The company said DetermaRx orders increased to 444 in Q4 2021 from 289 in Q3 2021; annual test volume or a specific financial forecast was not provided in the supplied text.
Key risks include continued operating losses and dependence on additional financing; potential shareholder dilution; limited commercial revenue sources; uncertain physician adoption and payer coverage; clinical-trial and technology-transfer delays; COVID-19-related disruption; possible changes to FDA oversight of LDTs; intellectual-property and licensing risks; and significant contingent acquisition obligations. Medicare coverage and pricing for DetermaRx were in place, but Oncocyte reported it was out of network with commercial payers and recognized revenue from many non-Medicare payers only upon collection.
The independent auditors issued an unqualified opinion on the FY2021 financial statements. The auditor highlighted acquisition-related valuation of Chronix intangible assets and contingent consideration as critical audit matters. The auditor did not express an opinion on internal-control effectiveness; management stated that disclosure controls and internal control over financial reporting were effective as of December 31, 2021.
Investor verification priorities
- Confirm cash runway against the reported $35.6 million cash balance, $35.9 million operating cash use, spending plans, and subsequent financing activity.
- Review the assumptions and potential cash or equity settlement of the $76.7 million contingent-consideration liabilities, particularly the Chronix earnouts.
- Track payer collections, reimbursement and coverage beyond Medicare, and the revenue-recognition policy for non-Medicare DetermaRx claims.
- Assess whether test orders, clinical evidence, and adoption translate into sustainable revenue and improved gross margins, rather than relying on licensing revenue or test-order growth alone.
- Monitor clinical, regulatory, and technology-transfer milestones for DetermaIO, DetermaCNI, and the Life Technologies collaboration, including development costs and commercialization rights.